Cyteir Therapeutics Ownership 2024 | Who Owns Cyteir Therapeutics Now?
Institutional Ownership
57.38%
Insider Ownership
6.64%
Retail Ownership
35.98%
Institutional Holders
32.00
Cyteir Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NOVO HOLDINGS A/S | 11.17% | 7.45% | 3,940,413 | - | - | 112,892,832,000 | Mar 31, 2023 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 9.03% | 0.00% | 3,183,697 | - | - | 46,000 | Mar 31, 2023 |
| BML CAPITAL MANAGEMENT, LLC | 8.92% | 4.95% | 3,146,296 | 3,146,296 | 100.00% | 5,726,259,000 | Mar 31, 2023 |
| OUP MANAGEMENT CO., LLC | 6.97% | 8.93% | 2,459,572 | - | - | 4,476,421,000 | Mar 31, 2023 |
| FMR LLC | 6.39% | 0.00% | 2,252,331 | -656,045 | -22.56% | 4,099,242,000 | Mar 31, 2023 |
| AVIDITY PARTNERS MANAGEMENT LP | 5.00% | 0.11% | 1,764,100 | -31,700 | -1.77% | 3,210,662,000 | Mar 31, 2023 |
| NEWTYN MANAGEMENT, LLC | 2.70% | 0.34% | 952,947 | -67,053 | -6.57% | 1,734,364,000 | Mar 31, 2023 |
| VANGUARD GROUP INC | 1.66% | - | 584,783 | - | - | 1,064,305,000 | Mar 31, 2023 |
| LAURION CAPITAL MANAGEMENT LP | 1.02% | 0.00% | 359,500 | - | - | 654,290,000 | Mar 31, 2023 |
| RENAISSANCE TECHNOLOGIES LLC | 0.50% | 0.00% | 176,034 | -53,159 | -23.19% | 320,000 | Mar 31, 2023 |
| ALDEBARAN CAPITAL, LLC | 0.43% | 0.28% | 151,239 | 151,239 | 100.00% | 275,255,000 | Mar 31, 2023 |
| CAAS CAPITAL MANAGEMENT LP | 0.43% | 0.01% | 150,406 | -309,373 | -67.29% | 273,739,000 | Mar 31, 2023 |
| EVERCORE WEALTH MANAGEMENT, LLC | 0.42% | 0.01% | 146,676 | - | - | 266,950,000 | Mar 31, 2023 |
| MORGAN STANLEY | 0.35% | - | 125,203 | 94,931 | 313.59% | 227,869,000 | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.34% | - | 119,032 | 1,900 | 1.62% | 216,638,000 | Mar 31, 2023 |
| RBF CAPITAL, LLC | 0.33% | 0.02% | 117,295 | -33,987 | -22.47% | 213,477,000 | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | 0.28% | 0.03% | 100,000 | 100,000 | 100.00% | 182,000,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 0.24% | 0.00% | 83,776 | -95,590 | -53.29% | 152,000 | Mar 31, 2023 |
| BLACKROCK INC. | 0.23% | - | 81,246 | 1,902 | 2.40% | 147,868,000 | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 69,584 | -50,000 | -41.81% | 126,643,000 | Mar 31, 2023 |
Cyteir Therapeutics's largest institutional shareholder is NOVO HOLDINGS A/S, holding 11.17% of the company's total share outstanding, currently valued at $112.89B. The top 10 institutional shareholders own together 53.35% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OUP MANAGEMENT CO., LLC | 6.97% | 8.93% | 2,459,572 | - | - | 4,476,421,000 | Mar 31, 2023 |
| NOVO HOLDINGS A/S | 11.17% | 7.45% | 3,940,413 | - | - | 112,892,832,000 | Mar 31, 2023 |
| BML CAPITAL MANAGEMENT, LLC | 8.92% | 4.95% | 3,146,296 | 3,146,296 | 100.00% | 5,726,259,000 | Mar 31, 2023 |
| NEWTYN MANAGEMENT, LLC | 2.70% | 0.34% | 952,947 | -67,053 | -6.57% | 1,734,364,000 | Mar 31, 2023 |
| ALDEBARAN CAPITAL, LLC | 0.43% | 0.28% | 151,239 | 151,239 | 100.00% | 275,255,000 | Mar 31, 2023 |
| AVIDITY PARTNERS MANAGEMENT LP | 5.00% | 0.11% | 1,764,100 | -31,700 | -1.77% | 3,210,662,000 | Mar 31, 2023 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.19% | 0.03% | 67,990 | 67,990 | 100.00% | 123,742,000 | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | 0.28% | 0.03% | 100,000 | 100,000 | 100.00% | 182,000,000 | Mar 31, 2023 |
| RBF CAPITAL, LLC | 0.33% | 0.02% | 117,295 | -33,987 | -22.47% | 213,477,000 | Mar 31, 2023 |
| CAAS CAPITAL MANAGEMENT LP | 0.43% | 0.01% | 150,406 | -309,373 | -67.29% | 273,739,000 | Mar 31, 2023 |
| CANNELL CAPITAL LLC | 0.06% | 0.01% | 19,684 | - | - | 35,825,000 | Mar 31, 2023 |
| EVERCORE WEALTH MANAGEMENT, LLC | 0.42% | 0.01% | 146,676 | - | - | 266,950,000 | Mar 31, 2023 |
| LAURION CAPITAL MANAGEMENT LP | 1.02% | 0.00% | 359,500 | - | - | 654,290,000 | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 69,584 | -50,000 | -41.81% | 126,643,000 | Mar 31, 2023 |
| ECOR1 CAPITAL, LLC | 0.12% | 0.00% | 43,823 | 43,823 | 100.00% | 79,758,000 | Mar 31, 2023 |
| LINDBROOK CAPITAL, LLC | 0.01% | 0.00% | 2,006 | - | - | 3,651,000 | Mar 31, 2023 |
| RENAISSANCE TECHNOLOGIES LLC | 0.50% | 0.00% | 176,034 | -53,159 | -23.19% | 320,000 | Mar 31, 2023 |
| FMR LLC | 6.39% | 0.00% | 2,252,331 | -656,045 | -22.56% | 4,099,242,000 | Mar 31, 2023 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 9.03% | 0.00% | 3,183,697 | - | - | 46,000 | Mar 31, 2023 |
| TWO SIGMA ADVISERS, LP | 0.07% | 0.00% | 26,000 | - | - | 47,320,000 | Mar 31, 2023 |
The largest Cyteir Therapeutics shareholder by % of total assets is OUP MANAGEMENT CO., LLC. The company owns 2.46M shares of Cyteir Therapeutics (CYT), representing 8.93% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 8.92% | 4.95% | 3,146,296 | 3,146,296 | 100.00% | 5,726,259,000 | Mar 31, 2023 |
| ALDEBARAN CAPITAL, LLC | 0.43% | 0.28% | 151,239 | 151,239 | 100.00% | 275,255,000 | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | 0.28% | 0.03% | 100,000 | 100,000 | 100.00% | 182,000,000 | Mar 31, 2023 |
| MORGAN STANLEY | 0.35% | - | 125,203 | 94,931 | 313.59% | 227,869,000 | Mar 31, 2023 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.19% | 0.03% | 67,990 | 67,990 | 100.00% | 123,742,000 | Mar 31, 2023 |
| ECOR1 CAPITAL, LLC | 0.12% | 0.00% | 43,823 | 43,823 | 100.00% | 79,758,000 | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | 0.19% | - | 67,539 | 42,722 | 172.15% | 122,921,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.01% | - | 4,825 | 4,825 | 100.00% | 8,782,000 | Mar 31, 2023 |
| NORTHERN TRUST CORP | 0.05% | - | 18,984 | 4,077 | 27.35% | 34,551,000 | Mar 31, 2023 |
| BLACKROCK INC. | 0.23% | - | 81,246 | 1,902 | 2.40% | 147,868,000 | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.34% | - | 119,032 | 1,900 | 1.62% | 216,638,000 | Mar 31, 2023 |
| FEDERATED HERMES, INC. | 0.00% | - | 208 | 208 | 100.00% | 379,000 | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | 0.00% | - | 98 | 1 | 1.03% | 178,000 | Mar 31, 2023 |
| JPMORGAN CHASE & CO | 0.00% | - | 496 | - | - | 1,000,000 | Mar 31, 2023 |
| STATE STREET CORP | 0.07% | - | 23,853 | - | - | 43,412,000 | Mar 31, 2023 |
| VANGUARD GROUP INC | 1.66% | - | 584,783 | - | - | 1,064,305,000 | Mar 31, 2023 |
| TWO SIGMA ADVISERS, LP | 0.07% | 0.00% | 26,000 | - | - | 47,320,000 | Mar 31, 2023 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 9.03% | 0.00% | 3,183,697 | - | - | 46,000 | Mar 31, 2023 |
| LINDBROOK CAPITAL, LLC | 0.01% | 0.00% | 2,006 | - | - | 3,651,000 | Mar 31, 2023 |
| LAURION CAPITAL MANAGEMENT LP | 1.02% | 0.00% | 359,500 | - | - | 654,290,000 | Mar 31, 2023 |
As of Mar 31 2023, Cyteir Therapeutics's largest institutional buyer is BML CAPITAL MANAGEMENT, LLC. The company purchased 3.15M stocks of CYT, valued at $5.73B.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | - | - | - | -2,492,118 | -100.00% | - | Mar 31, 2023 |
| FMR LLC | 6.39% | 0.00% | 2,252,331 | -656,045 | -22.56% | 4,099,242,000 | Mar 31, 2023 |
| CAAS CAPITAL MANAGEMENT LP | 0.43% | 0.01% | 150,406 | -309,373 | -67.29% | 273,739,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 0.24% | 0.00% | 83,776 | -95,590 | -53.29% | 152,000 | Mar 31, 2023 |
| NEWTYN MANAGEMENT, LLC | 2.70% | 0.34% | 952,947 | -67,053 | -6.57% | 1,734,364,000 | Mar 31, 2023 |
| RENAISSANCE TECHNOLOGIES LLC | 0.50% | 0.00% | 176,034 | -53,159 | -23.19% | 320,000 | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 69,584 | -50,000 | -41.81% | 126,643,000 | Mar 31, 2023 |
| RBF CAPITAL, LLC | 0.33% | 0.02% | 117,295 | -33,987 | -22.47% | 213,477,000 | Mar 31, 2023 |
| AVIDITY PARTNERS MANAGEMENT LP | 5.00% | 0.11% | 1,764,100 | -31,700 | -1.77% | 3,210,662,000 | Mar 31, 2023 |
| ERGOTELES LLC | - | - | - | -30,148 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -21,044 | -100.00% | - | Mar 31, 2023 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | - | - | - | -14,400 | -100.00% | - | Mar 31, 2023 |
| CITIGROUP INC | - | - | - | -246 | -100.00% | - | Mar 31, 2023 |
| OUP MANAGEMENT CO., LLC | 6.97% | 8.93% | 2,459,572 | - | - | 4,476,421,000 | Mar 31, 2023 |
| NOVO HOLDINGS A/S | 11.17% | 7.45% | 3,940,413 | - | - | 112,892,832,000 | Mar 31, 2023 |
| CANNELL CAPITAL LLC | 0.06% | 0.01% | 19,684 | - | - | 35,825,000 | Mar 31, 2023 |
| EVERCORE WEALTH MANAGEMENT, LLC | 0.42% | 0.01% | 146,676 | - | - | 266,950,000 | Mar 31, 2023 |
| LAURION CAPITAL MANAGEMENT LP | 1.02% | 0.00% | 359,500 | - | - | 654,290,000 | Mar 31, 2023 |
| LINDBROOK CAPITAL, LLC | 0.01% | 0.00% | 2,006 | - | - | 3,651,000 | Mar 31, 2023 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 9.03% | 0.00% | 3,183,697 | - | - | 46,000 | Mar 31, 2023 |
As of Mar 31 2023, Cyteir Therapeutics's biggest institutional seller is BAKER BROS. ADVISORS LP. The company sold -2.49M shares of CYT, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 8.92% | 4.95% | 3,146,296 | 3,146,296 | 100.00% | 5,726,259,000 | Mar 31, 2023 |
| ALDEBARAN CAPITAL, LLC | 0.43% | 0.28% | 151,239 | 151,239 | 100.00% | 275,255,000 | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | 0.28% | 0.03% | 100,000 | 100,000 | 100.00% | 182,000,000 | Mar 31, 2023 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.19% | 0.03% | 67,990 | 67,990 | 100.00% | 123,742,000 | Mar 31, 2023 |
| ECOR1 CAPITAL, LLC | 0.12% | 0.00% | 43,823 | 43,823 | 100.00% | 79,758,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.01% | - | 4,825 | 4,825 | 100.00% | 8,782,000 | Mar 31, 2023 |
| FEDERATED HERMES, INC. | 0.00% | - | 208 | 208 | 100.00% | 379,000 | Mar 31, 2023 |
Cyteir Therapeutics's largest new institutional shareholder by number of shares is BML CAPITAL MANAGEMENT, LLC, purchased 3.15M shares, valued at $5.73B, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | - | - | - | -2,492,118 | -100.00% | - | Mar 31, 2023 |
| ERGOTELES LLC | - | - | - | -30,148 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -21,044 | -100.00% | - | Mar 31, 2023 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | - | - | - | -14,400 | -100.00% | - | Mar 31, 2023 |
| CITIGROUP INC | - | - | - | -246 | -100.00% | - | Mar 31, 2023 |
Cyteir Therapeutics's largest sold out institutional shareholder by shares sold is BAKER BROS. ADVISORS LP, sold -2.49M shares, valued at -, as of undefined.
Cyteir Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 1.33% | 696,189 | - | - | Mar 31, 2024 |
| Humankind Benefit Corp | 0.63% | 13,934 | 3,089 | 28.48% | Dec 31, 2023 |
| Comstock Funds, Inc. | 0.47% | 10,000 | - | - | Jan 31, 2024 |
| Collaborative Investment Series Trust | 0.26% | 39,828 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.17% | 1,419,670 | - | - | Jan 31, 2024 |
| ETFis Series Trust I | 0.09% | 131,621 | - | - | Jan 31, 2024 |
| GABELLI EQUITY TRUST INC | 0.07% | 90,000 | - | - | Dec 29, 2023 |
| RYDEX VARIABLE TRUST | 0.02% | 29,276 | -14,968 | -33.83% | Dec 31, 2023 |
| PRAXIS MUTUAL FUNDS | 0.01% | 162,730 | 69,820 | 75.15% | Dec 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.01% | 32,800 | - | - | Mar 28, 2024 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.01% | 575,915 | -37,845 | -6.17% | Dec 31, 2023 |
| FIDELITY SECURITIES FUND | 0.01% | 826,758 | - | - | Jan 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 451,123 | - | - | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.01% | 24,535 | -19,769 | -44.62% | Dec 31, 2023 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 113,244 | - | - | Feb 29, 2024 |
| ALLSPRING FUNDS TRUST | 0.00% | 1,306,990 | - | - | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.00% | 24,710 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.00% | 17,000 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 857,079 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 1,192 | - | - | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 608,665 | - | - | Dec 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 11,795 | - | - | Mar 31, 2024 |
| BNY Mellon ETF Trust | 0.00% | 38,916 | - | - | Mar 28, 2024 |
| RBB FUND, INC. | 0.00% | 116,434 | - | - | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 134,330 | - | - | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 4,526 | -15 | -0.33% | Dec 31, 2023 |
| WILMINGTON FUNDS | 0.00% | 4,885 | - | - | Jan 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 127,870 | - | - | Jan 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 15,972 | - | - | Jan 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 641 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 6,691 | - | - | Mar 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 22,834 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 5,209 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 24,359 | - | - | Feb 29, 2024 |
| Global X Funds | 0.00% | 5,222 | - | - | Jan 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 470 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 11,066 | - | - | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 4,100 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 146 | - | - | Mar 31, 2024 |
| COLUMBIA FUNDS SERIES TRUST I | 0.00% | 197,611 | - | - | Feb 29, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 145,559 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 399 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 61,891 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 3,754 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 629 | - | - | Feb 29, 2024 |
| VALIC Co I | 0.00% | 6,923 | - | - | Feb 29, 2024 |
| FIDELITY SUMMER STREET TRUST | 0.00% | 7,254 | - | - | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 77 | - | - | Dec 31, 2023 |
| Mercer Funds | 0.00% | 125,300 | - | - | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 48 | - | - | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 2,978 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 4,950 | - | - | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 300 | - | - | Mar 28, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 2,294 | - | - | Jan 31, 2024 |
| HARTFORD MUTUAL FUNDS INC/CT | 0.00% | 74,330 | - | - | Jan 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 573 | - | - | Feb 29, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 500 | - | - | Mar 31, 2023 |
| RYDEX VARIABLE TRUST | 0.00% | 9 | - | - | Dec 31, 2023 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 16,100 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 18,871 | - | - | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 2,059 | - | - | Mar 31, 2024 |
| PRUDENTIAL INVESTMENT PORTFOLIOS 2 | 0.00% | 1,141 | - | - | Jan 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 5,402 | - | - | Mar 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 5,017 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 4,868 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 64,109 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 10,846 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 253 | - | - | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 52 | - | - | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 657 | - | - | Jan 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,627 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 4,145 | - | - | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 4,473 | - | - | Mar 31, 2024 |
| Meeder Funds | 0.00% | 3 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 2,592 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 2,314 | - | - | Mar 28, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 1,000 | - | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 984 | - | - | Mar 31, 2024 |
Cyteir Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 696.19K shares, compromising 1.33% of its total assets.
Cyteir Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 23 | 32 | 6.67% |
| 31 Dec, 22 | 30 | -16.67% |
| 30 Sep, 22 | 36 | -10.00% |
| 30 Jun, 22 | 40 | -20.00% |
| 31 Mar, 22 | 50 | 4.17% |
| 31 Dec, 21 | 48 | 26.32% |
| 30 Sep, 21 | 38 | 18.75% |
| 30 Jun, 21 | 32 | - |
| 31 Dec, 20 | - | -100.00% |
| 30 Sep, 20 | 1 | - |
| 30 Jun, 20 | 1 | - |
| 31 Mar, 20 | 1 | - |
| 31 Dec, 19 | 1 | - |
| 30 Sep, 19 | 1 | - |
| 30 Jun, 19 | 1 | - |
| 31 Mar, 17 | - | - |
| 30 Jun, 16 | - | -100.00% |
| 31 Mar, 16 | 1 | - |
| 31 Dec, 15 | - | -100.00% |
| 30 Sep, 15 | 262 | 0.77% |
| 30 Jun, 15 | 260 | 3.59% |
| 31 Mar, 15 | 251 | -3.46% |
| 31 Dec, 14 | 260 | 0.78% |
| 30 Sep, 14 | 258 | 13.66% |
| 30 Jun, 14 | 227 | 3.18% |
| 31 Mar, 14 | 220 | -2.65% |
| 31 Dec, 13 | 226 | 1514.29% |
As of 31 Mar 23, 32 institutions are holding Cyteir Therapeutics's shares, representing an increase of 6.67% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 23 | 20,239,636 | -0.95% |
| 31 Dec, 22 | 20,434,585 | -3.37% |
| 30 Sep, 22 | 21,146,877 | -4.64% |
| 30 Jun, 22 | 22,176,521 | -0.16% |
| 31 Mar, 22 | 22,212,031 | -0.59% |
| 31 Dec, 21 | 22,344,756 | 13.63% |
| 30 Sep, 21 | 19,664,776 | 18.51% |
| 30 Jun, 21 | 16,593,322 | - |
| 31 Dec, 20 | - | -100.00% |
| 30 Sep, 20 | 3,183,697 | - |
| 30 Jun, 20 | 3,183,697 | - |
| 31 Mar, 20 | 3,183,697 | - |
| 31 Dec, 19 | 3,183,697 | - |
| 30 Sep, 19 | 3,183,697 | - |
| 30 Jun, 19 | 3,183,697 | - |
| 31 Mar, 17 | - | - |
| 30 Jun, 16 | - | -100.00% |
| 31 Mar, 16 | 940 | - |
| 31 Dec, 15 | - | -100.00% |
| 30 Sep, 15 | 62,779,315 | -2.80% |
| 30 Jun, 15 | 64,589,762 | 1.87% |
| 31 Mar, 15 | 63,403,782 | 0.91% |
| 31 Dec, 14 | 62,831,915 | -2.45% |
| 30 Sep, 14 | 64,412,138 | 96.79% |
| 30 Jun, 14 | 32,732,133 | 0.32% |
| 31 Mar, 14 | 32,626,716 | 0.38% |
| 31 Dec, 13 | 32,503,877 | 2949.73% |
Cyteir Therapeutics (CYT) has 20.24M shares outstanding as of 31 Mar 23, down -0.95% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 23 | 57.38% | -0.80% |
| 31 Dec, 22 | 57.84% | -3.50% |
| 30 Sep, 22 | 59.94% | -4.75% |
| 30 Jun, 22 | 62.93% | -37.07% |
| 31 Mar, 22 | 100.00% | 56.92% |
| 31 Dec, 21 | 63.73% | -36.27% |
| 30 Sep, 21 | 100.00% | - |
| 30 Jun, 21 | 100.00% | - |
| 31 Dec, 20 | - | -100.00% |
| 30 Sep, 20 | 100.00% | - |
| 30 Jun, 20 | - | - |
| 31 Mar, 20 | - | - |
| 31 Dec, 19 | - | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 17 | - | - |
| 30 Jun, 16 | - | - |
| 31 Mar, 16 | - | - |
| 31 Dec, 15 | - | - |
| 30 Sep, 15 | - | - |
| 30 Jun, 15 | - | - |
| 31 Mar, 15 | - | - |
| 31 Dec, 14 | - | - |
| 30 Sep, 14 | - | - |
| 30 Jun, 14 | - | - |
| 31 Mar, 14 | - | - |
| 31 Dec, 13 | - | - |
As of 31 Mar 23, Cyteir Therapeutics is held by 57.38% institutional shareholders, representing a -0.80% negative growth compared to 31 Dec 22.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 23 | 6 | - |
| 31 Dec, 22 | 6 | -33.33% |
| 30 Sep, 22 | 9 | 12.50% |
| 30 Jun, 22 | 8 | -61.90% |
| 31 Mar, 22 | 21 | 31.25% |
| 31 Dec, 21 | 16 | 60.00% |
| 30 Sep, 21 | 10 | - |
| 30 Jun, 21 | - | - |
| 31 Dec, 20 | - | - |
| 30 Sep, 20 | - | - |
| 30 Jun, 20 | - | - |
| 31 Mar, 20 | - | - |
| 31 Dec, 19 | - | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 17 | - | - |
| 30 Jun, 16 | - | - |
| 31 Mar, 16 | - | - |
| 31 Dec, 15 | - | -100.00% |
| 30 Sep, 15 | 66 | -15.38% |
| 30 Jun, 15 | 78 | -8.24% |
| 31 Mar, 15 | 85 | -9.57% |
| 31 Dec, 14 | 94 | -52.76% |
| 30 Sep, 14 | 199 | 180.28% |
| 30 Jun, 14 | 71 | -14.46% |
| 31 Mar, 14 | 83 | 2666.67% |
| 31 Dec, 13 | 3 | 200.00% |
6 institutional shareholders have increased their position in CYT stock as of 31 Mar 23 compared to 6 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 23 | 8 | -33.33% |
| 31 Dec, 22 | 12 | -14.29% |
| 30 Sep, 22 | 14 | 7.69% |
| 30 Jun, 22 | 13 | 44.44% |
| 31 Mar, 22 | 9 | - |
| 31 Dec, 21 | 9 | 50.00% |
| 30 Sep, 21 | 6 | - |
| 30 Jun, 21 | - | - |
| 31 Dec, 20 | - | - |
| 30 Sep, 20 | - | - |
| 30 Jun, 20 | - | - |
| 31 Mar, 20 | - | - |
| 31 Dec, 19 | - | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 17 | - | - |
| 30 Jun, 16 | - | - |
| 31 Mar, 16 | - | - |
| 31 Dec, 15 | - | -100.00% |
| 30 Sep, 15 | 90 | -10.00% |
| 30 Jun, 15 | 100 | 3.09% |
| 31 Mar, 15 | 97 | 3.19% |
| 31 Dec, 14 | 94 | 623.08% |
| 30 Sep, 14 | 13 | -84.88% |
| 30 Jun, 14 | 86 | 14.67% |
| 31 Mar, 14 | 75 | 2400.00% |
| 31 Dec, 13 | 3 | -50.00% |
8 institutional shareholders have reduced their position in CYT stock as of 31 Mar 23 compared to 12 in the previous quarter (a -33.33% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 23 | 32 | 6.67% | 20,239,636 | -0.95% | 57.38% | -0.80% | 6 | - | 8 | -33.33% |
| 31 Dec, 22 | 30 | -16.67% | 20,434,585 | -3.37% | 57.84% | -3.50% | 6 | -33.33% | 12 | -14.29% |
| 30 Sep, 22 | 36 | -10.00% | 21,146,877 | -4.64% | 59.94% | -4.75% | 9 | 12.50% | 14 | 7.69% |
| 30 Jun, 22 | 40 | -20.00% | 22,176,521 | -0.16% | 62.93% | -37.07% | 8 | -61.90% | 13 | 44.44% |
| 31 Mar, 22 | 50 | 4.17% | 22,212,031 | -0.59% | 100.00% | 56.92% | 21 | 31.25% | 9 | - |
| 31 Dec, 21 | 48 | 26.32% | 22,344,756 | 13.63% | 63.73% | -36.27% | 16 | 60.00% | 9 | 50.00% |
| 30 Sep, 21 | 38 | 18.75% | 19,664,776 | 18.51% | 100.00% | - | 10 | - | 6 | - |
| 30 Jun, 21 | 32 | - | 16,593,322 | - | 100.00% | - | - | - | - | - |
| 31 Dec, 20 | - | -100.00% | - | -100.00% | - | -100.00% | - | - | - | - |
| 30 Sep, 20 | 1 | - | 3,183,697 | - | 100.00% | - | - | - | - | - |
| 30 Jun, 20 | 1 | - | 3,183,697 | - | - | - | - | - | - | - |
| 31 Mar, 20 | 1 | - | 3,183,697 | - | - | - | - | - | - | - |
| 31 Dec, 19 | 1 | - | 3,183,697 | - | - | - | - | - | - | - |
| 30 Sep, 19 | 1 | - | 3,183,697 | - | - | - | - | - | - | - |
| 30 Jun, 19 | 1 | - | 3,183,697 | - | - | - | - | - | - | - |
| 31 Mar, 17 | - | - | - | - | - | - | - | - | - | - |
| 30 Jun, 16 | - | -100.00% | - | -100.00% | - | - | - | - | - | - |
| 31 Mar, 16 | 1 | - | 940 | - | - | - | - | - | - | - |
| 31 Dec, 15 | - | -100.00% | - | -100.00% | - | - | - | -100.00% | - | -100.00% |
| 30 Sep, 15 | 262 | 0.77% | 62,779,315 | -2.80% | - | - | 66 | -15.38% | 90 | -10.00% |
| 30 Jun, 15 | 260 | 3.59% | 64,589,762 | 1.87% | - | - | 78 | -8.24% | 100 | 3.09% |
| 31 Mar, 15 | 251 | -3.46% | 63,403,782 | 0.91% | - | - | 85 | -9.57% | 97 | 3.19% |
| 31 Dec, 14 | 260 | 0.78% | 62,831,915 | -2.45% | - | - | 94 | -52.76% | 94 | 623.08% |
| 30 Sep, 14 | 258 | 13.66% | 64,412,138 | 96.79% | - | - | 199 | 180.28% | 13 | -84.88% |
| 30 Jun, 14 | 227 | 3.18% | 32,732,133 | 0.32% | - | - | 71 | -14.46% | 86 | 14.67% |
| 31 Mar, 14 | 220 | -2.65% | 32,626,716 | 0.38% | - | - | 83 | 2666.67% | 75 | 2400.00% |
| 31 Dec, 13 | 226 | 1514.29% | 32,503,877 | 2949.73% | - | - | 3 | 200.00% | 3 | -50.00% |
Cyteir Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Cyteir Therapeutics's stock was made by Leonard Braden Michael on Mar 19 2024, selling - shares at - per share (valued at -). The last insider buy of CYT was made by Leonard Braden Michael on Mar 25 2024, buying 170,589 shares at $2.95 per share (worth $503.24K).
Cyteir Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | 11 | 11 | 100.00% |
| Q4 2023 | 8 | 8 | 100.00% |
| Q3 2023 | - | 5 | - |
| Q2 2023 | - | 12 | - |
| Q1 2023 | 13 | - | - |
| Q4 2022 | 3 | 2 | 150.00% |
| Q3 2022 | - | 1 | - |
| Q2 2022 | 5 | - | - |
| Q1 2022 | 13 | - | - |
| Q4 2021 | 13 | 1 | 1300.00% |
| Q2 2021 | 11 | 38 | 28.95% |
| Q4 2015 | 7 | 10 | 70.00% |
| Q3 2015 | 6 | - | - |
| Q2 2015 | 13 | 3 | 433.33% |
| Q1 2015 | 9 | 8 | 112.50% |
| Q4 2014 | 5 | - | - |
| Q3 2014 | 5 | - | - |
| Q2 2014 | 13 | 4 | 325.00% |
| Q1 2014 | 7 | 4 | 175.00% |
| Q4 2013 | 5 | - | - |
11 total buy trades, and 11 total sell trades (buy/sell ratio of 1.00%) were made by Cyteir Therapeutics's insiders, as of Q1 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | 1 | - | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | 5 | - |
| Q2 2023 | - | 12 | - |
| Q1 2023 | - | - | - |
| Q4 2022 | 1 | - | - |
| Q3 2022 | - | 1 | - |
| Q2 2022 | 4 | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | 11 | - | - |
| Q2 2021 | 3 | - | - |
| Q4 2015 | - | - | - |
| Q3 2015 | - | - | - |
| Q2 2015 | - | - | - |
| Q1 2015 | - | 4 | - |
| Q4 2014 | - | - | - |
| Q3 2014 | - | - | - |
| Q2 2014 | - | - | - |
| Q1 2014 | - | 2 | - |
| Q4 2013 | - | - | - |
As of Q1 2024, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Cyteir Therapeutics's stocks.
Cyteir Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| GBIO | Generation Bio Co. |
| CSBR | Champions Oncology, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| NKTX | Nkarta, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| ELYM | Eliem Therapeutics, Inc. |
CYT Ownership FAQ
Who Owns Cyteir Therapeutics?
Cyteir Therapeutics is owned by institutional shareholders (57.38%), insiders (6.64%), and public (35.98%). The largest institutional shareholder of Cyteir Therapeutics is NOVO HOLDINGS A/S (11.17% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (1.33% of total shares).
Who are the major institutional shareholders of Cyteir Therapeutics?
Cyteir Therapeutics's major institutional shareholders are NOVO HOLDINGS A/S, PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO, BML CAPITAL MANAGEMENT, LLC, OUP MANAGEMENT CO., LLC, and FMR LLC. The top five shareholders own together 42.48% of the company's share outstanding.
How many Cyteir Therapeutics shareholders are there?
As of Mar 2023, there are 32 institutional shareholders of Cyteir Therapeutics.
What percentage of Cyteir Therapeutics is owned by NOVO HOLDINGS A/S?
NOVO HOLDINGS A/S owns 3.94M shares of Cyteir Therapeutics, representing 11.17% of the company's total shares outstanding, valued at $112.89B (as of Mar 2023).
What percentage of Cyteir Therapeutics is owned by PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO?
As of Mar 2023, PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO holds 3.18M shares of Cyteir Therapeutics (CYT), compromising 9.03% of the company, valued at $46K.
What percentage of Cyteir Therapeutics is owned by BML CAPITAL MANAGEMENT, LLC?
BML CAPITAL MANAGEMENT, LLC is the third largest holder of Cyteir Therapeutics. The company owns 3.15M of the company's shares outstanding (worth $5.73B).